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Bile acidsChronic bowel disease can co-exist with severe autoimmune hepatitis (AIH) in an absence of primary sclerosing
cholangitis. Genetic background may contribute to this overlap syndrome. We previously have shown that the
deﬁciency of iPLA2β causes an accumulation of hepatocyte apoptosis, and renders susceptibility for acute liver in-
jury.We here testedwhether AIH induction in iPLA2β-nullmice could result in intestinal injury, andwhether bile
acid metabolism was altered. Control wild-type (WT) and female iPLA2β-null (iPLA2β−/−) mice were intrave-
nously injected with 10 mg/kg concanavalinA (ConA) or saline for 24 h. ConA treatment of iPLA2β−/− mice
caused massive liver injury with increased liver enzymes, ﬁbrosis, and necrosis. While not affecting WT mice,
ConA treatment of iPLA2β−/−mice caused severe duodenal villous atrophy concomitant with increased apopto-
sis, cell proliferation, globlet cell hyperplasia, and endotoxin leakage into portal vein indicating a disruption of in-
testinal barrier. With the greater extent than in WT mice, ConA treatment of iPLA2β−/−mice increased jejunal
expression of innate response cytokines CD14, TNF-α, IL-6, and SOCS3 as well as chemokines CCL2 and the
CCL3 receptor CCR5. iPLA2β deﬁciency in response to ConA-induced AIH caused a signiﬁcant decrease in hepatic
and biliary bile acids, and this was associated with suppression of hepatic Cyp7A1, Ntcp and ABCB11/Bsep and
upregulation of intestinal FXR/FGF15 mRNA expression. The suppression of hepatic Ntcp expression together
with the loss of intestinal barrier could account for the observed bile acid leakage into peripheral blood. Thus, en-
teropathy may result from acute AIH in a susceptible host such as iPLA2β deﬁciency.
© 2015 Elsevier B.V. All rights reserved.AIH,autoimmunehepatitis;ALT,
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The liver plays a major role in the defense against pathological in-
sults and disease, such as, viral infection,metabolic syndrome, and auto-
immune diseases, and thus this organ is prone to injury triggered by
accumulated fat deposition and inﬂammatory cells. The injury to liver
and bile ducts causes hepatobiliary autoimmune disease including pri-
mary biliary cirrhosis, primary sclerosing cholangitis (PSC), and autoim-
mune hepatitis (AIH), and this disease has an inherited element and
clusters among families [1,2]. It is known that PSC is the most common
hepatobiliary disease seen in association with inﬂammatory bowel dis-
ease (IBD), with 5% of all patients with IBD having PSC, and most pa-
tients with PSC ultimately develop IBD, usually chronic ulcerative
colitis (UC) [2]. An overlap syndrome of PSC and AIH has also been
seen in patients with UC, and severe AIH in an absence of PSC can lead
to the development of UC with up to 16% of patients with AIH also hav-
ing UC [3]. As patients with well-established AIH can develop PSC [4],
and that those AIH patients with PSC in the background can develop
progressive liver failure from AIH [5], this suggests that the common
1647L. Jiao et al. / Biochimica et Biophysica Acta 1852 (2015) 1646–1657mechanism of AIH and PSC overlap syndrome for UC and IBD may in-
volve a cholestatic phenotype with cholangiopathy and histologic
changes of bile duct injury [3,6] as well as alteration in bile acids within
the enterohepatic system [7]. Intestinal inﬂammation and injury has
been reported in experimental cirrhosis [8], as well as in patients with
decompensated [9] and alcoholic [10] cirrhosis, and the latter has
been shown to be associated with alteration in bile acid metabolism.
No experimental data have ever been presented to report the involve-
ment of AIH in IBD to conﬁrm patient studies [3], and whether the
mechanism is genetically dependent.
In deﬁning a pathogenic mechanism for a contribution of AIH to
bowel disease, we designed amouse AIHmodel by using a combination
of concanavalin A (ConA) [11], and a genetically susceptible transgenic
mouse model [12]. ConA induces hepatitis in mice is by an activation
of T cells and macrophages withmassive granulocyte and CD4 T cell in-
ﬁltration which leads to apoptosis and necrosis in the hepatocytes and
biliary epithelial cells. The latter corresponds to the cholestatic pheno-
type which is regulated by bile acids [13,14]. Hence, AIH pathogenesis
may involve alteration in bile acid metabolism in the enterohepatic
loop [10,14] that may play a pivotal role in intestinal homeostasis lead-
ing to bowel injury and disease [8–10].
In evaluating a genetically susceptiblemousemodel, we chose group
VIA calcium-independent phospholipase A2 (iPLA2) with alterative
names of Pla2G6 or iPLA2β [15], because it has multiple physiologically
important functions in numerous cell types and tissues [16]. iPLA2β cat-
alyzes phospholipids to generate 1). lysophosphatidylcholine (LPC)
which acts as a ‘ﬁnd-me’ signal for removal of apoptotic cells by mono-
cytes [17,18], and 2). lysophosphatidic acid (LPA) plays a role in themi-
gration ofmonocytes [19,20], and of ovarian cancer cells [21]. Despite of
the anticipated dysfunction with iPLA2β deﬁciency, iPLA2β-null mice
with the deletion of the lipase-containing exon 9 live normally, but
they have defects in glucose homeostasis [15], gain lesser body weight
[22], and develop neuroaxonal dystrophy [23] as they age to 1–2 years
old. In line with a decrease of LPC leading to a defect in the removal of
apoptotic hepatocytes, results from our laboratory have shown that he-
patic apoptosis was indeed increased in the livers of iPLA2β-null mice
together with increased inﬂammation and susceptibility for endotoxin
injury [24] (manuscript under preparation). Because apoptosis is the
predominantmechanism of liver cell death during AIH [25], we hypoth-
esize that the deﬁciency of iPLA2βwould represent a genetic susceptible
preconditioning for AIH that could lead to bowel injury.
Here we compared the extent of AIH liver injury induced by ConA
betweenwild-type (WT) and iPLA2β-null (iPLA2β−/−) mice, and deter-
minedwhether AIH observed in liverwas associatedwith abnormalities
in the intestine and colon in regards to epithelial damage, proliferation
and bile acid contents. We demonstrated that iPLA2β deﬁciency sensi-
tized the effects of ConA in promoting liver injury as well as duodenal
apoptosis, villous atrophy, intestinal inﬂammation, goblet cell hyperpla-
sia, and leakage of endotoxin into portal vein. Alteration of bile acids
was observed in liver, bile, intestine, feces, and peripheral blood during
ConA and iPLA2β-deﬁciency sensitization. Gene expression analysis re-
vealed a feedback regulation of hepatic bile acid synthesis by intestinal
FXR/FGF15 axis. Thus, ConA-induced AIH in a susceptible host with
iPLA2β deﬁciency led to enteropathy which was associated with alter-
ation in bile acid metabolism. Our data support the notion that the
liver-to-gut axis injury due to AIH in susceptible individuals may lead
to bowel disease.
2. Materials and methods
2.1. Animals and treatment
iPLA2β−/− mice were kind gifts from Dr. John Turk (Washington
University School of Medicine, St. Louis, Missouri, USA). The breeding
and genotyping was performed according to the published work [15].
Control WT mice were mice with iPLA2β+/+ phenotype. All mice werehoused at the animal facility of the University Heidelberg. Female
mice at 13–16 months old were used. For an AIH induction, mice were
intravenously injected via tail veinwith 10mg/kg Con A (SigmaAldrich,
Taufkirchen, Germany) or saline. Blood, liver, bile, intestine, colon, and
feces were harvested 24 h after ConA administration. All animal exper-
iments were approved by the Animal Care and Use Committee of the
University of Heidelberg.
2.2. Biochemical assays
Serumwas obtained after centrifugation at 5000 g for 15min. Serum
activities of alanine aminotransferase (AST), aspartate aminotransferase
(AST), lactate dehydrogenase (LDH), and alkaline phosphatase (AP)
were measured spectrophotometrically by using diagnostic kits from
Randox (Krefeld, Germany).
2.3. Histology and immunohistochemistry (IHC)
Liver, intestine and colon specimens were ﬁxed in 10% formalin at
room temperature for 18 h, and embedded in parafﬁn, and parafﬁn
blocks were cut into 5 μm sections. Sections were stained with hema-
toxylin and eosin (H&E) for histology. For Sirius-red staining of the
liver, sections were stained with 0.1% Direct Red 80 Solution (Sigma Al-
drich) in a saturated solution of picric acid. For mucin staining of intes-
tine, slides were stained with alcian blue-periodic acid schiff (AB-PAS)
reagents (Sigma Aldrich) according to standard procedure.
For IHC, after deparafﬁnizing and hydration, sections were treated
with 10 mM citrate buffer (pH 6.0) and heated to 98 °C for 20 min. En-
dogenous peroxidasewas blocked by treating sectionswith 3% H2O2 for
10min at room temperature prior to an exposure to a primary antibody
overnight at 4 °C. Rabbit primary antibodies used for IHC were cleaved
caspase-3 (1:800; cat# 9664, Cell Signaling), α-SMA (1:250; E184, Epi-
tomics), CK19 (1:100; cat# ab133496, Abcam), Ki67 (1:100; cat#
ab16667, Abcam), CD3 (1:300; cat# ab5690, Abcam), and CD45R
(1:200; cat# ab64100, Abcam). Sections for cleaved caspase-3 staining
were stained by using an Abcam Avidin-Biotin Complex kit (cat#
ab64261), and the rest of antibodies sections were incubated with a
goat anti-rabbit secondary Abcam antibody (cat# ab6721) for 1 h at
room temperature. Positive stainingwas detected by diaminobenzidine.
Slides were counterstained with hematoxylin prior to mounting.
Light microscopy was used to visualize stained cells with an Olym-
pus IX 50 microscope. The quantiﬁcation of Sirius-red- and α-SMA-
positive areas in liver was performed by using Image J. For computer-
ized image analyses of intestine, the number of stained cells on a surface
area of epithelial cells were determined by using the Olympus Cell^F
software. A picture of one ﬁeld on a slide taken with a 20X objective
corresponded to 0.6 mm2 on the tissue. The number of stained cells
on each slide was counted from ten randomly selected ﬁelds. Data
were presented as the number of stained cells per mm2 of intestinal ep-
ithelium. Evaluation of IHC sections was performed in a blind manner.
2.4. Bile acid proﬁling using LC-MS/MS
Samples were subjected to extraction using a published method
[26], and bile acid concentrations were determined by using liquid-
chromatography mass spectrometry (LC-MS/MS) according to a pub-
lished method [27]. Brieﬂy, the separation of bile acids was achieved
by using a Phenomenex Luna C18 column (100 mm × 2.0 mm, 3 μm)
ﬁtted on a separation module of a Waters 2695. Binary solvents were
80% H2O/MeOH with 8 mM ammonium acetate, pH 8.0 (solvent
A) and 95% MeOH/H2O with 8 mM ammonium acetate, pH 8.0 (solvent
B). The ﬂow rate was maintained at 0.2 mL/min, and the gradient was
started with 100% solvent A for 2.5 min, changed to 100% solvent B in
1 min, held for 16.5 min, and returned to the initial condition in
3 min. Separated fractions were detected on-line by an electrospray
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2.5. Gene expression analyses
Total RNA was isolated by using the QIAGEN RNeasy Mini kit
(Qiagen, Hilden, Germany). cDNA was synthesized from 2 μg RNA by
using a Maxima First Strand cDNA synthesis kit (Fermentas, St. Leon-
Rot, Germany). Gene expression was analyzed by quantitative real-
time polymerase chain reaction (q-RT-PCR) using Applied Biosystems
TaqMan® gene expression assays with TaqMan® Universal PCRMaster
Mix, and run on an Applied Biosystem 7500. The expression level of tar-
gets in quadruplets was calculated using theΔ–Ct transformationmeth-
od, and determined as a ratio of the target gene normalized to the
house-keeping gene GAPDH.
2.6. Western blot analyses
Tissue homogenates were obtained after centrifugation at 13,000 g
at 4 °C for 15 min, and proteins were determined by using Bio-Rad
proteinDC kit (Bio-Rad laboratories, Munich, Germany). Proteins were
separated by gel electrophoresis and transferred onto a PDVF mem-
brane. Blots were probed with a primary antibody at 1:1000 dilution
overnight at 4 °C followed by a secondary antibody. Primary antibodies
used for Western blot included a rabbit antibody against iPLA2β (cat #
sc-14463, Santa Cruz), cleaved caspase 3 (cat# 9664, Cell Signaling),
CCL2 (cat #2027, Cell Signaling), and PPARγ (cat #2435, Cell Signaling).
Proteins were visualized using the Luminata Forte ECL reagent
(Millipore, Darmstadt, Germany). Image J was used to quantify the den-
sity of protein bands of the targets and loading control GAPDH, and the
ratio of protein target/GADPH was calculated.
2.7. Measurement of LPS in mouse serum
The concentrations of LPS in mouse portal vein serum were deter-
mined by using Mouse Lipopolysaccharides (LPS) ELISA Kit cat #
MBS040441 (BiozolGmbH, Eching,Germany) according tomanufacturer's
instructions. In brief, 50 μl serum and HRP-conjugated reagent were
added into a pyrogen-free microplate well. After 60-min incubation at
37 °C, the sample mixture was added with 100 μl of substrate solution
followed by an addition of 50 μl stop buffer after 16-min incubation.
The absorbance was then measured at 450 nm.
2.8. Statistics
Results were expressed as mean ± SEM. Signiﬁcance was accepted
at p b 0.05. For lipidomics data, statistical signiﬁcance for multiple com-
parisonswas computed using the Rmultcomp formultiple comparisons
of all pairwise differences of mean (Tukey contrasts). For the rest of the
data, signiﬁcance using ANOVA with Turkey's post hoc test for multiple
comparisons was determined by using GraphPad Prism 5.
3. Results
3.1. iPLA2β deﬁciency increases susceptibility towards ConA-induced liver
injury
We have previously found that iPLA2β−/−micewere susceptible for
endotoxin liver injury [24] (manuscript under preparation), we there-
fore determined whether this would be the case for ConA-induced
AIH. With a low dose of ConA (10mg/kg) injected for 24 h, ConA nearly
had no effects on activities of liver enzymes (ALT, AST, LDH and AP) in
control WT mice, while marked elevation of these activities was
observed in iPLA2β−/− mice (Fig. 1A). This increased liver injury was
consistent with histological changes seen in H&E stained liver sections
(Fig. 1B). ConA-treated WT livers showed minimal pathologicalabnormalities while ConA-treated mutant livers showed macroscopic
lesions with necrotic areas (marked with N) and a wider sinusoid
space (Fig. 1B). ConA treatment established an AIH as seen by the pres-
ence of recruited lymphocytes stained with CD3 T cell and CD45R B cell
markers, and the extent of lymphocyte inﬁltration was greater in
iPLA2β−/− knockout mice (Fig. 1C).
AIH causes liver inﬂammation and is commonly associatedwith pro-
gressive ﬁbrosis. We consistently observed that the livers of iPLA2β−/−
mice showed increased collagen deposition seen by Sirius-red staining
(Fig. 1D) as well as activation of hepatic stellate cells seen by α-SMA
IHC (Fig. 1E). Quantiﬁcation of both ﬁbrosis markers represented as %
positive area showed that ConA treatment induced ﬁbrosis in both WT
andmutant mice, but with a greater extent in mutant than in WTmice.
To further investigate the mechanism of iPLA2β in ConA-induced
AIH, we analyzed cell proliferation by assessing an S phase maker Ki67
in livers. We found that IHC staining of Ki67 was positive on the lym-
phocytes in livers of saline- and ConA-treated iPLA2β−/− mice, and
the latter with increased lymphocyte inﬁltration with many more cells
showing positive for Ki67 (Fig. 1F). Proliferative lymphocytes were
seen surrounding the portal tract in mutant livers indicating moderate
inﬂammation by iPLA2β deﬁciency alone, and in response to ConAmas-
sive lymphocyte inﬁltration was seen around portal tract and nearby
adjacent parenchyma. At the portal tract, ConA-induced lymphocytes
may induce an activation of ductular reaction of the bile ducts resulting
in a cholestatic phenotype [13]. By IHC staining of cytokeratin 19
(CK19), a marker of biliary epithelial cells, we consistently observed
moderately increased CK19 staining in iPLA2β−/− livers when com-
paredwithWT livers (Fig. 1G).Marked increased CK19 stainingwas ob-
served in livers of ConA-treatedmutant micewith a greater extent than
those of WT mice. These ﬁndings indicated that iPLA2β was critical in
the homeostasis of hepatobiliary system, and that its deﬁciency ren-
dered susceptibility for ConA-induced injury in the hepatocytes and bil-
iary epithelial cells. Hence, iPLA2β−/− mice undergoing AIH were a
suitable model system for further investigation on abnormalities in
the intestine and alteration in bile acid proﬁles.
3.2. Lack of iPLA2β disrupts intestinal integrity associated with increased
apoptosis
The genetic deletion of exon 9 in iPLA2β gene led to a complete ab-
sence of iPLA2β protein detectable at 85 KDa and mRNA expression in
the duodenum of iPLA2β−/− compared with that of WT mice (Fig. 2A).
Interestingly, ConA treatment slightly increased expression of iPLA2β
protein in the mutant intestine suggesting a feedback regulation of
iPLA2β presumably necessary for the proliferation of lymphocytes trig-
gered by ConA [28]. Histological analysis showed that ConA treatment
nearly had no effects in WT duodenum, but caused severe damage in
mutant intestinal epithelial cells associated with exposed lamina
propria, shorter villi, disturbedmucus membrane, andmucosal atrophy
(Fig. 2B). We hypothesize that deﬁciency of iPLA2β producing a de-
crease in the ‘ﬁnd-me-signal’ LPC could result in an accumulation of ap-
optotic cells in intestine. Compared with WT duodenum, we
consistently observed an increase in apoptosis in mutant duodenum
as seen by IHC (markedwith black arrowheads) andWestern blot anal-
ysis of cleaved caspase 3 (Fig. 2C). In a greater extent in themutant than
in theWTduodenum, ConA treatment further increased the shedding of
apoptotic epithelial cells as seen by cleaved caspase 3 IHC showing pos-
itive staining towards the top of the villi. This sensitization to ConAwas
not due to changes in anti-apoptosis proteins, since we observed no dif-
ference in duodenal mRNA expression of anti-apoptosis TNFAIP3 and
Bcl2 in ConA-treatedWT andConA-treatedmutantmice (Supplementa-
ry Fig. S1).
As we previously observed increased proliferative lymphocytes in
livers of ConA-treatedmutantmice (Fig. 1C and F), we further evaluated
the extent of cell proliferation in the intestine. ConA treatment of mu-
tantmice increased the number of Ki67 (+) cells in the duodenal crypts
Fig. 1. Hypersensitivity towards ConA-induced autoimmune hepatitis by iPLA2β deﬁciency. WT and iPLA2β−/−mice were intravenously injected with 10 mg/kg ConA or saline for 24 h.
Our experimental system comprised of 4 groups: ConA-treated iPLA2β−/− , ConA-treatedWT, saline-treated iPLA2β−/− , and saline-treatedWTmice. A. ALT, AST, LDH and AP activities in
serum samples of treated mice from four groups. Data are mean ± SEM (N= 6–8): ***, p b 0.001 vsWT. B. Representative H&E staining of the livers of treated mice from four groups. N
indicates necrosis area. C. CD3 and CD45R IHC staining of the livers of ConA-treatedWT or iPLA2β−/−mice. D. Sirius-red staining of the livers (upper panel) and its quantiﬁcation (lower
panel) of treatedmice from four groups. Data aremean±SEM (N=3–4); *, p b 0.05; ***,p b 0.001. E.α-SMA IHC staining of the livers (upper panel) and its quantiﬁcation (lower panel) of
treatedmice from four groups. Data aremean±SEM(N=3–4); ***,p b 0.001. F. Ki67 IHC staining of the livers of treatedmice from four groups. G. CK19 IHC stainingof the livers of treated
mice from four groups. Scale bar in histological pictures represents 200 μm.
1649L. Jiao et al. / Biochimica et Biophysica Acta 1852 (2015) 1646–1657(Fig. 2D) and colonic crypts (Fig. 2E) to a greater extent than that of WT
mice. This observation likely revealed a simultaneous activation of the
regeneration of enterocytes and colonocytes in order to compensate
for epithelial cell loss due to ConA-induced villous damage. Notably,
compared with WT mice it was also observed that the colon of mutant
mice already had an elevated number of Ki67 (+) cells which was not
further increased by ConA (Fig. 2E), emphasizing an inherent effect of
iPLA2β deﬁciency on colonic proliferation. This lack of ConA effect in
the mutant colon may indicate an anatomical distance away from the
liver as to compare with the effect observed in the mutant duodenum.
3.3. Effects of iPLA2β deﬁciency on ConA-induced inﬂammatory response in
the intestine
In an association with increased duodenal apoptosis and atrophy
(Fig. 2B), we further determined whether ConA combined with iPLA2β
deﬁciency increased an inﬂammatory response by qRT-PCR analyses.
ConA treatment ofmutantmice caused and induction of innate immune
response as seen by an increase in jejunalmRNA expression of an innate
response receptor CD14, TNF-α, IL-6, and suppressor of cytokine signal-
ing 3 (SOCS3) when compared with Con-treated WT mice (Fig. 3A).
ConA treatment however increased IL-10 and IL-1βmRNA expressionto the same extent in both WT and mutant mice (Supplementary
Fig. S2A). As chemokines contribute to the pathogenesis of AIH by
directing the migration and positioning of inﬂammatory and immune
cells, we analyzed jejunal expression of various chemokines. The in-
volvement of CCL3/CCR5 axis in ConA-induced inﬂammatory response
was observed in mutant jejunum with a tendency and a signiﬁcant in-
crease of CCL3 and CCR5, respectively (Fig. 3B). Among other
chemokines including CXCL12, VCAM1, CCR1, CCL4, and CCL5, ConA
treatment increased expression of these chemokines to the same extent
among WT and mutant mice (Fig. 3B, and Supplementary Fig. S2B). No
ConA response was observed among WT and mutant intestine for lym-
phocyte markers CD4, CD8, endothelial cell marker CD34, as well as
dendritic cell marker CD11b, CD11c, and F480 (Supplementary Fig. S2
C). Unlike the observation in the liver (Fig. 1F), ConA treatment ap-
peared not to sensitize the inﬁltration of lymphocytes and immune
cells to the mutant intestine suggesting that ConA primarily induced
the innate immune response in this organ in an iPLA2β-dependent
manner.
The most affected chemokine was CC chemokine ligand 2 (CCL2) or
monocyte chemoattractant protein1 (MCP1) as seen by an increased
expression of CCL2 protein and mRNA in the jejunum of ConA-treated
mutant mice when compared with that in ConA-treated WT mice
Fig. 2. Lack of iPLA2β causes duodenal villous atrophy by increasing apoptosis. Experimental conditionswere the same as described in Fig. 1. A.Western blot analyses (left), protein quan-
tiﬁcation (middle) and qRT-PCR analysis (right) for iPLA2β expression in the duodenum of treated mice from four groups. Data are mean ± SEM (N= 3–8); *, p b 0.05; **, p b 0.01; ***,
p b 0.001. B. Representative histological images from H&E-stained duodenal sections from treated mice from four groups. C. Cleaved caspase 3 IHC staining (left), Western blot analyses
(right, upper panel), protein quantiﬁcation (right, lower panel) in the duodenum of treated mice from four groups. Data are mean ± SEM (N= 3–5); **, p b 0.01; ***, p b 0.001. D. Rep-
resentativeKi67 staining of the duodenal crypts of treatedmice from four groups. Data aremean±SEM (N=4); **, p b 0.01. E. Representative Ki67 staining of the colonic crypts of treated
mice from four groups. Data are mean ± SEM (N= 4); **, p b 0.01. Scale bar in histological pictures represents 200 μm.
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of the CCL2 receptor CCR2 to the same extent in WT and mutant mice.
Aswe observed that immune cell inﬁltration to the intestinewas not in-
volved during ConA and iPLA2β deﬁciency sensitization (Supplementa-
ry Fig. S2B), we interpret these results that the increased jejunal MCP1
would unlikely be derived from activity of immune cells, but rather
from the accumulated apoptotic intestinal epithelial cells themselves
in order to attract phagocytes for their effective removal.
iPLA2β catalyzes phosphatidic acid to LPA which has been shown to
mediate cell migration [19–21]. To delineate possible role of iPLA2β-
derived LPA during ConA and iPLA2β-deﬁciency sensitization, we
analyzed the expression of an intracellular receptor LPA peroxisome
proliferator activated receptorγ (PPARγ) [29]. ConA treatment of
iPLA2β−/− mice caused a signiﬁcant decrease in jejunal protein and
mRNA expression of PPARγ, while no effect was observed in ConA-
treated WT mice (Fig. 3D). We further determined expression of class
B scavenger receptor CD36 which is under the transcriptional control
of PPARγ [30], and CD36 has been shown to play a role in mediating
the recognition and elimination of apoptotic cells [31]. Consistently,
CD36 mRNA expression was signiﬁcantly decreased in the jejunum of
ConA-treated mutants when compared with that of ConA-treated WT
mice (Fig. 3D). Thus, ConA and iPLA2β-deﬁciency sensitization in intes-
tinewas likely associatedwith accumulated apoptosis due the defects in
‘ﬁne-me’ signal LPC as well as the defects in LPA-activation of PPARγ
and CD36.3.4. iPLA2β-deﬁcient mice treatedwith ConA exhibit severely disturbedmu-
cus membrane, duodenal goblet cell hyperplasia, and endotoxin leakage in-
to portal vein
Intestinal goblet cells secretemucins to form amucus layer as a host-
defense barrier against variety of enteric pathogens, and inﬂammation
of mucous membrane can contribute to the development of diarrhea.
To determine whether there was dysfunction in goblet cell-mediated
mucin secretion during ConA-induced intestinal injury in mutants, we
stained acidic and neutral mucins in the duodenum, ileum, and colon
by using alcian blue-periodic acid schiff (AB-PAS) reagents. We ob-
served AB-PAS blue stains on themucusmembrane layer on the luminal
side of intestine (indicated by red arrows) and on the goblet cells
(Fig. 4). Compared with saline treatment, ConA treatment of mutant
mice increased the number of mucin-containing globlet cells in all the
tissues examined (Fig. 4A–C). In the duodenum of ConA-treatedmutant
mice, there was an increase of blue-stained mucins on the mucus
membrane and on the goblet cells, and the latter was shown with an
increase of the number of mucin-containing globlet cells when com-
pared with that of ConA-treated WT mice (Fig. 4A). This increase was
suggestive of either an active mucin secretion or new synthesis of mu-
cins, or both, during ConA and iPLA2β-deﬁciency sensitization. In the
ileum of ConA-treated mutant mice, an increase of number of mucin-
containing globlet cells was also observed while no disruption of
mucus membrane was observed (Fig. 4B). Finally, no changes in
Fig. 3. iPLA2β deﬁciency sensitizes ConA-induced inﬂammatory response in the intestine. Experimental conditionswere the same as described in Fig. 1. A. qRT-PCR analysis of CD14, TNFα,
IL-6 and SOCS3mRNA expression in the jejunum of treatedmice from four groups. Data aremean± SEM (N=6–8); *, p b 0.05; ***, p b 0.001. B. qRT-PCR analysis of CCL3, CCR5, CXCL12,
and VCAM1 mRNA expression in the jejunum of treated mice from four groups. Data are mean ± SEM (N= 6–8); *, p b 0.05; ***, p b 0.001. C. Western blot analyses normalized with
GADPH (left), qRT-PCR analysis (middle) of CCL2 expression, and qRT-PCR analysis of CCR2 expression (right) in the jejunum of treated mice from four groups. Data are mean ± SEM
(N= 3–8); *, p b 0.05; **, p b 0.01. D. Western blot analyses normalized with GADPH (left), qRT-PCR analysis (middle) of PPARγ expression, and qRT-PCR analysis of CD36 expression
(right) in the jejunum of treated mice from four groups. Data are mean ± SEM (N= 3–8); *, p b 0.05; **, p b 0.01; ***, p b 0.001.
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served in the colon of WT and mutant mice treated with ConA (Fig. 4C).
These results showed the presence of disrupted mucus membrane and
goblet cell hyperplasia in the duodenum, and the severity became lesser
in the distal intestine and colon. Thus, the duodenum was the most
affected because of its closer proximity to the liver where AIH sensitiza-
tion was initiated.
To elucidate the mechanism responsible for goblet cell hyperplasia in
the intestine of ConA-treated iPLA2β−/−mice,we analyzed twokey target
genes shown to regulate the differentiation of globlet cells, namely,
Kruppel-like factor 4 (Klf4) and cyclin D2. Klf4 is a zinc ﬁnger transcrip-
tion factor required for intestinal goblet cell differentiation [32]. Here,
we found that ConA treatment of mutant mice increased intestinal Klf4
mRNA expression to a greater extent than that of WT mice (Fig. 4D).
Cyclin D2 is an inhibitor of cyclin-dependent kinases whose activity is re-
quired for cell cycle G1/S transition, and the transcriptional upregulation
of cyclin D2 has been shown to protect mice from developing intestinal
goblet cellmetaplasia [33]. ConA treatment ofWTmice induced amarked
upregulation of intestinal cyclin D2 (Ccnd2) mRNA, but failing to so in
iPLA2β−/−mice (Fig. 4E). The observed defect in Ccnd2 activation in the
mutants by ConA was consistent with the increased goblet cell
hyperplasia (Fig. 4 A), and also the observed increases of Ki67 (+) prolif-
eration in intestinal crypts (Fig. 2D). Hence, our results showed that ConA
and iPLA2β-deﬁciency sensitization induced intestinal goblet cell
hyperplasia by a mechanism involving goblet cell differentiation at least
in part mediated by Klf4 and cyclin D2.The observed disruption of duodenalmucusmembrane during ConA
and iPLA2β-deﬁciency sensitization shown in Fig. 4A would allow a
leakage of luminal bacteria into intestine and entering into portal vein.
Consistently, LPS levels in the portal vein serum obtained from ConA-
treated iPLA2β−/− mice were increased compared with those in the
serum obtained from ConA-treated WT mice (Fig. 4F). These effects
were not statistically signiﬁcant for serum LPS obtained fromperipheral
blood (data not shown).
3.5. iPLA2β deﬁciency alone and in response to ConA causes alteration in
bile acid metabolism and transport in liver and intestine
To this end, iPLA2β deﬁciency sensitized the effects of ConA increas-
ing the injury on the hepatocytes and biliary epithelial cells with necro-
sis, ﬁbrosis and ductular reaction (Fig. 1), and this was associated with
intestinal apoptosis (Fig. 2), inﬂammation (Fig. 3), and goblet cell hy-
perplasia (Fig. 4) with the most effects observed in the duodenum.
Since bile is secreted from liver into duodenal lumen, we further inves-
tigated whether these abnormalities would be associated with alter-
ation in bile acid metabolism. Bile acids are synthesized from
cholesterol by Cyp7A1 in the liver into primary bile acids: cholic acid
(CA), muricholic acid (muriCA), chenodeoxycholic acid (CDCA), which
is conjugated with glycine and taurine amino acids to form glyco- and
tauro-bile acids. After bile acid secretion into gut lumen, gut bacteria
perform deconjugation and dehydroxylation to produce secondary
bile acids deoxycholic acid (DCA), lithocholic acid (LCA), and 7-oxo-
Fig. 4. iPLA2β-deﬁcient mice treatedwith ConA exhibit disruptedmucusmembrane, goblet cell hyperplasia and endotoxin leakage to portal vein. Experimental conditions were the same
as described in Fig. 1. A. Representative AB/PAS staining of theduodenumof treatedmice from four groups showing goblet cells (upper panel),mucus secretion (indicated by arrowheads),
and the quantiﬁcation of mucin-containing duodenal goblet cell number (lower panel). Data are mean± SEM (N= 3–4); *, p b 0.05; **, p b 0.01; ***, p b 0.001. B. Representative AB/PAS
staining of the ileum of treatedmice from four groups showing goblet cells (upper panel), mucus secretion (arrowheads), and the quantiﬁcation ofmucin-containing ileal goblet cell num-
ber (lower panel). Data are mean ± SEM (N= 3–4); ***, p b 0.001. C. Representative AB/PAS staining of the colon of treated mice from four groups showing goblet cells (upper panel),
mucus secretion (arrowheads), and the quantiﬁcation of mucin-containing colonic goblet cell number (lower panel). Data are mean ± SEM (N = 3–4); *, p b 0.05; ***, p b 0.001. D.
qRT-PCR analysis of Klf4 gene in the jejunum of treated mice from four groups. Data are mean ± SEM (N= 6–8); *, p b 0.05. E. qRT-PCR analysis of Ccnd2 gene in the jejunum of treated
mice from four groups. Data are mean ± SEM (N = 6–8); **, p b 0.01. F. ELISA analysis of LPS levels in portal vein serum. Data are mean ± SEM (N = 6–8); ***, p b 0.001. Scale bar in
histological pictures represents 100 μm.
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to the liver via portal vein. In liver, 7-oxo-LCA is metabolized into
CDCA and ursodeoxycholic acid (UDCA) by a steroid dehydrogenase.
The metabolic loop through liver and gut constitutes an enterohepatic
cycle of bile acids. In our experimental system, we utilized LC/MS-MS
method to determine bile acid concentrations in liver, bile, intestine,
feces, and peripheral serum (Table 1). By using the formula denoted in
Table 1, the effects of iPLA2β deﬁciency with and without ConA could be
determined as indicated by an up- or down-arrow symbol, and the net
change was represented as μg/g or μg/mL as well as % calculated based
on total bile acids obtained from saline-treated WT mice.
In the liver, ConA treatment of WTmice caused marked elevation
of most bile acids including the major bile acids in mice, namely CA,
muriCA, and their conjugates (Table 1). However ConA treatment
failed to elevate these bile acids in iPLA2β−/−mice, and this resulted
in a decrease in the response to ConA by iPLA2β deﬁciency as indicat-
ed in the last column of Table 1. With an exception, rather than a de-
crease we observed a weak increase of hydrophobic bile acids
CDCA + DCA and LCA. By combining the up and down response, a
net decrease of liver bile acids was obtained with 1303 μg/g liver or
72%. This decrease in liver was consistently observed with a net de-
crease of bile acids in the bile by 689 μg/mL or 55%. We further deter-
mined whether bile acid synthesis genes were affected in the liver. Weobserved a signiﬁcant decrease of Cyp7a1 mRNA expression when com-
paring ConA-treated WT with ConA-treated iPLA2β−/− livers
(Fig. 5A), and the opposite was found for the expression of the neg-
ative regulator small heterodimer partner (SHP). Hence, iPLA2β deﬁ-
ciency sensitized the effects of ConA by inhibiting bile acid synthesis
in the liver.
We further performed RT-PCR analysis to determine whether
bile acid transport genes were altered by ConA and iPLA2β
deﬁciency. We observed a signiﬁcant decreased mRNA expression
of Ntcp and ABCB11/Bsep during ConA and iPLA2β-deﬁciency sen-
sitization (Fig. 5B). The decreased expression of Ntcp, which up-
takes all conjugated bile acids from portal blood to hepatocytes,
could at least in part contribute to the observed decreases of bile
acids in the liver. Alternatively, the decreased expression of
ABCB11/Bsep, which exports bile acids from hepatocytes into bile
ducts, could in part contribute to the observed decreases of bile
acids in the bile. ConA also caused a decrease in expression of phos-
pholipid transport gene ABCB4 and MRP3 which exports bile acids
from hepatocytes to portal blood, no difference was found among
WT and mutant livers (Fig. 5B). No difference in liver FXR expres-
sion was observed among four treated groups (not shown).
Bile secreted from liver to gut lumen is mixed with fecal con-
tents, and some bile acids are reabsorbed by intestinal cells. In a
Table 1
Conjugated and unconjugated bile acids in livers, bile, intestine, feces, and serum of iPLA2β−/− and WTmice treated with saline or ConA.
Bile acidswere detected by LC-MS/MS as described inMaterials andmethods. Results were expressed in μg/g tissue and μg/mL bile or serum, and represented asmean± SEM (N=6–11).
Mice were treated with 10 mg/kg Con A or saline for 24 h.
Bile acid typea Saline Effect of iPLA2β
deﬁciency (μg/g or
μg/mL)a
ConA Response to ConA by
iPLA2β deﬁciency (μg/g or
μg/mL)b
WT iPLA2β−/− WT iPLA2β−/−
Liver
CA 35.3 ± 15.4 305.3 ± 145.2 ↑270 142.0 ± 49.4† 248.4 ± 144.1 ↓164
muriCA 576.9 ± 86.6 263.8 ± 50.8⁎ ↑313 942.6 ± 220.1 182.0 ± 52.5 ↓448
tauroCA 527.4 ± 151.2 399.8 ± 162.3 ↓128 999.8 ± 420.9† 545.9 ± 216.0# ↓326
tauromuriCA 504.4 ± 110. 576.9 ± 83.0 ↑73 671.4 ± 165.7 456.8 ± 70.2 ↓287
CDCA + DCA 0.09 ± 0.02 0.38 ± 0.05⁎ ↑0.3 0.12 ± 0.03 0.42 ± 0.08# ↑0.01
glycoCDCA + glycoDCA 0.019 ± 0.006 0.042 ± 0.010 ↓0.02 0.012 ± 0.006 0.024 ± 0.016 ↓0.01
tauroCDCA + tauroDCA 135.7 ± 43.9 120.7 ± 38.5 ↓15 169.1 ± 78.2 103.2 ± 30.5 ↓51
LCA 0.014 ± 0.011 0.100 ± 0.006 ↑0.09 0.023 ± 0.019 0.154 ± 0.112# ↑0.05
tauroLCA 0.40 ± 0.04 0.63 ± 0.15 ↑0.2 0.62 ± 0.07 0.81 ± 0.15 ↓0.04
UDCA 0.09 ± 0.04 0.38 ± 0.18 ↑0.3 0.7 ± 0.44 0.89 ± 0.90 ↓0.1
tauroUDCA 20.9 ± 6.9 38.1 ± 19.8 ↑17 32.9 ± 18.3 22.3 ± 8.25 ↓28
Net change in μg/g (% based on total 1801 μg/g
liver WT/sal)
↓95
(↓5%)
↓1303
(↓72%)
Bile
CA 217.7 ± 50.8 236.6 ± 88.3 ↑19 122.8 ± 25.7 111.5 ± 30.9 ↓30
muriCA 133.0 ± 36.5 147.8 ± 58.9 ↑15 88.7 ± 16.4 69.6 ± 18.9 ↓34
tauroCA 1.2 ± 0.1 1.3 ± 0.2 ↑0.1 1.8 ± 0.1 0.8 ± 0.1# ↓1.1
tauromuriCA 6.2 ± 0.9 6.0 ± 1.4 ↓0.2 8.0 ± 0.6 3.6 ± 0.6# ↓4.2
glycoCA 2.6 ± 0.5 2.9 ± 0.5 ↑0.3 4.1 ± 0.4 2.2 ± 0.4# ↓2.2
CDCA + DCA 19.6 ± 2 5.4 24.0 ± 3 3.2 ↑4.4 18.2 ± 3.1 19.3 ± 2.9 ↓3.3
glycoCDCA + glycoDCA 91.9 ± 19.0 100.4 ± 27.7§ ↑8.5 89.2 ± 6.6 22.8 ± 4.6# ↓75
tauroCDCA + tauroDCA 293.6 ± 37.5 289.0 ± 60.2§ ↓4.6 348.1 ± 21.8 126.4± 34.2# ↓217
UDCA 47.9 ± 15.4 50.2 ± 13.0 ↑2.3 39.1 ± 4.2 54.5 ± 9.3 ↑13
tauroLCA 1.1 ± 0.2 1.4 ± 0.4§ ↑0.3 1.1 ± 0.1 0.3 ± 0.1# ↓0.5
tauroUDCA 216.9 ± 39.0 214.6 ± 43.2 ↓2.3 258.3 ± 22.7 124.6 ± 28.5# ↓131
glycoUDCA 231.6 ± 43.7 254.3 ± 61.0 ↑23 344.9 ± 50.3 164.3 ± 33.2# ↓203
Net change in μg/mL (%based on total 1263 μg/mL
bile WT/sal)
↑65
(↑5%)
↓689
(↓55%)
Intestine
CA 209.6 ± 33.4 209.2 ± 40.1 ↑0.2 155.9 ± 45.2 94.1 ± 23.0 ↓58
muriCA 241.0 ± 62.9 100.1 ± 26.8 ↓82 178.7 ± 63.8 23.6 ± 16.6# ↓73
tauroCA 57.9 ± 14.1 2.4 ± 0.8⁎ ↓56 2.0 ± 0.6 1.2 ± 0.4 ↑55
tauromuriCA 38.7 ± 12.4 2.0 ± 0.6⁎ ↓37 2.8 ± 1.6 1.0 ± 0.3 ↑35
glycoCA 0.85 ± 0.20 0.04 ± 0.01⁎ ↓0.8 0.02 ± 0.01 0.01 ± 0.003 ↑0.8
glycomuriCA 0.28 ± 0.08 0.03 ± 0.01⁎ ↓0.3 0.006 ± 0.002 0.001 ± 0.0004 ↑0.3
CDCA + DCA 4.09 ± 1.36 1.69 ± 0.29⁎ ↓2 3.10 ± 0.90 0.54 ± 0.07# ↓0.2
glycoCDCA + glycoDCA 0.029 ± 0.009 0.003 ± 0.001⁎ ↓0.03 0.002 ± 0.001† 0.0003 ± 0.0001 ↑0.02
tauroCDCA + tauroDCA 19.82 ± 4.23 0.37 ± 0.10⁎ ↓20 0.31 ± 0.09† 0.15 ± 0.03 ↑19
LCA 0.14 ± 0.03 0.04 ± 0.009⁎ ↓0.1 0.029 ± 0.009† 0.017 ± 0.004 ↑0.1
tauroLCA 0.30 ± 0.006 0.04 ± 0.006⁎ ↓0.3 0.03 ± 0.01† 0.005 ± 0.002 ↑0.2
UDCA 7.56 ± 1.56 3.84 ± 0.85 ↓4 7.63 ± 2.53 1.13 ± 0.30# ↓3
tauroUDCA 76.04 ± 20.22 3.48 ± 1.39⁎ ↑73 1.02 ± 0.40† 0.77 ± 0.22 ↑72
glycoUDCA 0.069 ± 0.027 0.0048 ± 0.0023⁎ ↓0.06 0.0086 ± 0.0036† 0.017 ± 0.008 ↑0.1
Net change in μg/g (% based on total 650 μg/g
intestine WT/sal)
↓333
(↓51%)
↑48
(↑7%)
Feces
CA 8.8 ± 3.1 24.1 ± 6.8 ↑15 29.2 ± 11.3 39.3 ± 18.1 ↓5
muriCA 85.8 ± 6.3 86.6 ± 11.6 ↑0.8 105.4 ± 15.2 131.9 ± 29.6 ↑26
tauroCA 0.13 ± 0.06 0.41 ± 0.22⁎§ ↑0.3 0.24 ± 0.06 0.11 ± 0.01 ↓0.4
tauromuriCA 0.4 ± 0.1 1.4 ± 0.4 ↑1.0 0.7 ± 0.1 1.6 ± 0.5 ↓0.1
glycoCA 0.10 ± 0.04 0.40 ± 0.21 ↑0.3 0.56 ± 0.33 1.07 ± 0.59 ↑0.2
CDCA + DCA 12.2 ± 1.4 12.5 ± 1.8 ↑0.3 21.2 ± 3.1 10.7 ± 0.9# ↓11
glycoCDCA + glycoDCA 0.47 ± 0.10 0.37 ± 0.09 ↓0.1 0.53 ± 0.08 0.19 ± 0.04 ↓0.2
tauroCDCA+ tauroDCA 0.44 ± 0.12 1.01 ± 0.36 ↑0.6 0.61 ± 0.15 1.00 ± 0.39 ↓0.2
LCA 4.3 ± 0.4 4.7 ± 0.8§ ↑0.4 3.7 ± 0.4 1.7 ± 0.1# ↓2
Net change in μg/g (% based on total 113 μg/g
feces WT/sal)
↑19
(↑17%)
↑6.6
(↑5.8%)
Serum
CA 0.73 ± 0.4 1.4 ± 0.4 ↑0.7 0.68 ± 0.06 1.69 ± 0.46 ↑0.34
muriCA 0.76 ± 0.11 0.49 ± 0.1 ↓0.3 0.83 ± 0.1 4.4 ± 0.7# ↑3.8
tauroCA 0.81 ± 0.2 0.06 ± 0.1§ ↓0.8 0.24 ± 0.08 5.81 ± 0.5# ↑6.3
tauromuriCA 0.58 ± 0.14 0.29 ± 0.12§ ↓0.3 0.43 ± 0.14 3.43 ± 0.88# ↑3.2
glycoCA 0.003 ± 0.002 0.0007 ± 0.0005§ ↓0.02 0.002 ± 0.001 0.184 ± 0.007# ↑0.2
CDCA + DCA 0.07 ± 0.02 0.07 ± 0.02§ – 0.04 ± 0.01 0.87 ± 0.27# ↑0.8
tauroCDCA + tauroDCA 0.08 ± 0.01 0.05 ± 0.02 ↓0.03 0.06 ± 0.03 3.92 ± 1.33 ↑4
LCA 0.29 ± 0.011 0.50 ± 0.006§ ↑0.2 0.56 ± 0.019 1.21 ± 0.112 ↑0.4
UDCA 0.09 ± 0.02 0.10 ± 0.02 ↑0.01 0.07 ± 0.01 0.44 ± 0.09⁎ ↑0.4
(continued on next page)
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Table 1 (continued)
Bile acid typea Saline Effect of iPLA2β
deﬁciency (μg/g or
μg/mL)a
ConA Response to ConA by
iPLA2β deﬁciency (μg/g or
μg/mL)b
WT iPLA2β−/− WT iPLA2β−/−
tauroUDCA 0.02 ± 0.004 0.02 ± 0.002 – 0.02 ± 0.005 0.60 ± 0.22# ↑0.4
Net change in μg/mL (%based on total 3.4 μg/mL
serum WT/sal)
↓0.5
(↓13%)
↑20
(↑590%)
⁎ p b 0.05, saline-WT versus saline-iPLA2β−/−.
# p b 0.05, ConA-WT versus ConA-iPLA2β−/−.
§ p b 0.05, ConA-iPLA2β−/− versus saline-iPLA2β−/−.
† p b 0.05, ConA-WT versus saline-WT.
a Response to ConA by iPLA2β deﬁciency in μg/g or μg/mL =Mean Saline-iPLA2β−/−−Mean Saline-WT.
b Response to ConA by iPLA2β deﬁciency in μg/g or μg/mL = (Mean ConA-iPLA2β-/-−Mean Saline-iPLA2β-/-)− (Mean ConA-WT−Mean Saline-WT).
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bile acids CA and muriCA were decreased in the intestine in re-
sponse to ConA by iPLA2β deﬁciency; while most conjugated bile
acids were increased (Table 1). This resulted in a net increase of
bile acids by 48 μg/g or 7%. This net increase of bile acids may reﬂect
speciﬁc changes in bile acid transports, thus we further measuredFig. 5. iPLA2β deﬁciency in response to ConA causes alteration in regulators of bile acid synthesis
qRT-PCR analysis of CYP7A1, and SHP mRNA expression in livers of treated mice from four g
iPLA2β−/− (gray bar) mice (right panel). B. qRT-PCR analysis of Ntcp, ABCB11, ABCB4, and M
FGF15, and FXR mRNA expression in the jejunum of treated mice from four groups (left pane
bar) mice (right panel). D. qRT-PCR analysis of intestinal OSTα, OSTβ, and ASBT mRNA expres
*, p b 0.05, **, p b 0.01, ***, p b 0.001. The response to ConA in gene expression was calculated
(Mean ConA/WT−Mean Saline/WT) for WT mice.expression of intestinal bile acid transport genes as well as
farnesoid X-activated receptor (FXR). FXR is the major regulator
of negative feedback loop that controls bile acid synthesis in the
liver via an intestinal induction and release of ﬁbroblast growth
factor 15 (FGF15) into portal vein [34]. FGF15 in blood interacts
with FGFR4-Klotho complex at the hepatocyte plasma membraneand bile acid transporters. Experimental conditionswere the same as described in Fig. 1. A.
roups (left panel), and the response to ConA was compared among WT (white bar) and
RP3 mRNA expression in livers of treated mice from four groups. C. qRT-PCR analysis of
l), and the response to ConA was compared among WT (white bar) and iPLA2β−/− (gray
sion in the jejunum of treated mice from four groups. Data are mean ± SEM (N= 4−7);
based on the formula: (Mean ConA/iPLA2β−/--Mean Saline/iPLA2β−/−) for iPLA2β
−/−mice, and
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expression, and hence bile acid synthesis in liver. Here, we ob-
served that ConA sensitization by iPLA2β deﬁciency was associated
with a signiﬁcant increase in intestinal FXR and FGF15mRNA expression
(Fig. 5C). We surmise that intestinal FGF15 could repress Cyp7a1 expres-
sion in the liver (Fig. 5A) hence resulting in the observed decreased bile
acids in liver and bile (Table 1).
As for bile acid levels in feces, we observed a net increase of mainly
muriCA of 6.6 μg/g or 5.8% during ConA and iPLA2β-deﬁciency sensitiza-
tion. Thisweak increase rather than the expecteddecrease as seen in the
bile could be due to a multiple-fold dilution of bile acids from bile into a
much larger volume of thewhole feces.We further determined possible
alteration of bile acids transports in the intestine. In response to ConAby
iPLA2β deﬁciency, we observed a signiﬁcant decreased mRNA expres-
sion of OSTβ and only a tendency of a decrease for OSTα, and ASBT ex-
pression. OSTβ exports bile acids from enterocytes to portal blood thus
its decreased expression could lead to an intestinal accumulation of bile
acids.
As we demonstrated an increase of portal vein LPS in ConA-treated
iPLA2β-null mice (Fig. 4F), this provided a hint of a loss of intestinal bar-
rier associated with duodenal atrophy where intestinal bile acids may
leak into mesentery blood and subsequently into peripheral blood. In
line with this, we observed a net increase of bile acids in peripheral
blood from inferior vena cava by 20 μg/mL or 590%. Because that the
net decreases of bile acids in liver and bile could not explain this in-
crease in peripheral blood, we surmise that the loss of intestinal barrier
rather than damaged bile ducts would likely contribute to the bile acids
leaking outside the enterohepatic loop.
Finally, we also observed changes in bile acid proﬁles by iPLA2β de-
ﬁciency alone with a net decrease in the liver, and intestine by 5%, and
51%, respectively, and amild increase in bile and feces of 5% and 17%, re-
spectively (Table 1). These changes were associated with a signiﬁcant
decrease of SHP mRNA expression when comparing saline-treated WT
with saline-treated iPLA2β−/− livers (Fig. 5A). Thus, iPLA2β deﬁciency
alone appeared to have no overt abnormalities in terms of bile acid me-
tabolism consistent with nomarked pathology observed in liver and in-
testine of mutant mice (Figs. 1 and 2).
4. Discussion
We clearly demonstrated that iPLA2β deﬁciency elicited sensitiza-
tion towards ConA-induced AIH by causing hepatobiliary injurywith in-
creased releases of liver enzymes, apoptosis, lymphocyte inﬁltration,
hepatic ﬁbrosis, and ductular biliary expansion. This sensitization led
to intestinal villous atrophy, inﬂammation, and goblet cell hyperplasia
withmore prominent effects observed in the duodenum than in the dis-
tal intestine. This sensitization was associated with increased portal
vein LPS, suppressed levels of hepatic and biliary bile acids, but with
marked increases of bile acids in peripheral blood. The latter was likely
due to the loss of intestinal barrier and decreased bile acid transport into
hepatocytes as a result of suppressed hepatic Ntcp expression. Hence,
iPLA2β deﬁciency may represent a genetic susceptibility precondition
for AIHwhich leads to intestinal abnormalities resembling enteropathy.
Our data further demonstrated the regulation of hepatic bile acid syn-
thesis by intestinal FXR/FGF15 axis during AIH sensitization by iPLA2β
deﬁciency.
The mechanism of how iPLA2β deﬁciency renders susceptibility for
liver injury has been a subject in an on-going work in our laboratory
which is based on a link between accumulated apoptosis and develop-
ment of inﬂammation and autoimmune disease [35]. We found that
livers of iPLA2β−/−mice had increased apoptosis [24] with a moderate
lymphocyte inﬁltration (Fig. 1F), and that Kupffer cells isolated from
mutant mice secrete increased IFNγ and TNFα upon LPS stimulation
(unpublished data). Upon ConA treatment of iPLA2β−/−mice, liver lym-
phocytes (activated by ConA) together with Kupffer cells (activated by
iPLA2β deﬁciency) could augment the releases of cytokines therebyaggravating liver injury. Kupffer cells are known to play an important
role in ConA-induced AIH by an activation of the production of reactive
oxygen species [36] and CCL3 [37], both of which can induce innate im-
mune activation [38]. Being proximal to the liver, the duodenumwas the
most affected by iPLA2β deﬁciency and ConA sensitization, while inﬂam-
mation was increased in jejunum, and goblet cell hyperplasia was ob-
served in duodenum and ileum. It is plausible that activated Kupffer
cells and liver lymphocytes during this sensitized AIH may release pro-
inﬂammatory cytokines into intestinal tract which may in turn activate
intestinal macrophages which cause the observed abnormalities. This is
supported by a recent observation showing that activated macrophages
with IL-6 release disrupt intestinal barrier function in the duodenum of
patients with cirrhosis [9]. In line with this, the jejunum of ConA-treated
mutant mice showed increased innate response cytokines CD14, TNFα,
IL-6, and SOCS3, some of which contribute to IBD [39]. Activation of
CCL3/CCR5 axis was also observed associated with intestinal atrophy in
ConA-treatedmutantmice, and thismay be crucial in colitis-associatedﬁ-
broblast accumulation [40] and IBD [41]. Furthermore, mucus secreted by
intestinal goblet cells is critically involved in protection of intestinal mu-
cosa as a physical and chemical barrier preventing adherence of microbi-
ota and translocation of potential pathogens. Severely disturbed mucus
membrane observed in the duodenum of ConA-treated mutant mice
would allow the translocation of microbial toxins and endotoxin into in-
testinal mucosa, and into portal vein. The portal vein LPS may reach the
liver and aggravate further inﬂammation there.
Our work shed light on the functions of intestinal FXR and FGF15 on
their putative role as a metabolic regulator of bile acid synthesis in the
liver [34]. AIH sensitization by iPLA2β deﬁciency was associated with
an upregulation of intestinal FXR/FGF15 and downregulation of hepatic
Cyp7A1 expression, and the latter showing inhibited bile acid synthesis
was supported by the observed decreases of hepatic and biliary bile
acids by 55–72%. This occurred despite of the fact that we had observed
an increase in biliary ductular reaction detected by CK19 staining. Under
this condition, the expression of major bile acid transporters, such as
hepatic Ntcp, ABCB11/Bsep, and intestinal OSTβ, was also markedly
inhibited likely due to cytokines which were elevated in both organs
[42]. Suppressed Ntcp would result in an accumulation of bile acids in
portal vein, and this could be an additional mechanism for elevated
bile acids in periphery blood. Notably, despite of the decreases of most
bile acids in liver, the contents of CDCA + DCA and LCA in the liver
were increased either by iPLA2β deﬁciency alone or combined with
ConA, and this was associated with decreased SHP expression. These
conditions may indicate an inherent predisposition and toxic effects of
these hydrophobic bile acids [13], seen as lymphocyte inﬁltration and
mild ductular reaction in mutant livers.
In light of the reported anti-inﬂammatory effects of bile acids [43],
the observed decreases of hepatic and biliary bile acids may augment
the AIH injury sensitized by iPLA2β deﬁciency. This can be further sup-
ported by reports that cholic acid administration results in a delay in
the progression of acetaminophen-induced in liver injury [44], and a
bile acid as an FXR receptor sensor protects against ConA-induced AIH
[45]. During AIH injury sensitized by iPLA2β deﬁciency, we observed
an upregulation of intestinal FXR/FGF15 mRNA concomitant with an
increase of most conjugated bile acids in the intestine. This intestine-
speciﬁc activation, particularly by conjugated bile acids [46] may serve
as a protective mechanism in protecting mice from overt cholestasis
[47], and from gut barrier dysfunction [48] under this AIH sensitization.
In line with this notion, intestinal bile acids are thought to act as an
adaptation to reduce liver injury and cirrhosis [49]. Further experiments
are warranted to test this hypothesis by co-administration with cholate
or an FXR agonist to determine their protective effects against sensitized
AIH. Furthermore, the defect of microbiota function in fecal bile acid
metabolism has been shown to play a role in cirrhosis [14] and IBD
[50]. In the feces of ConA-treatedmutantmice, we observed an increase
of muriCA while most secondary bile acids including LCA were
decreased. This was suggestive of a defect in bacterial activity in the
1656 L. Jiao et al. / Biochimica et Biophysica Acta 1852 (2015) 1646–1657dehydroxytion of muriCA to LCA [51]. Furthermore, the observed in-
creases of bile acids in intestine and feces may evoke mucin secretion
[52] resulting in the observed goblet cell hyperplasia.
We unequivocally demonstrated bile acid leakage into peripheral
blood which was associated with duodenal atrophy and leakage of en-
dotoxin into portal vein. Our interpretation for the impaired intestinal
barrier as a mechanism for leaky bile acids in peripheral blood is sup-
ported by various clinical studies in that the serum contents of bile
acids are elevated in children with hepatic and intestinal diseases [53],
and in patients with IBD [54]. Much earlier work in the 1980's fails to
show an association between liver disease and severe IBD, where no
marked changes were seen in portal vein bile acids [55]. This contradic-
tion to our study could be due to the fact thatwe used amuch improved
LC-MS/MS method for bile acid detection. In the 1990's, it was already
shown that the contents of bile acids in duodenal juice from infants
with hepatitiswere signiﬁcantly lower [56], which is in linewith the ob-
served decreases of hepatic and biliary bile acids in ConA-sensitizedmu-
tant mice. While our experimental model emphasizing iPLA2β as the
genetic background for susceptibility for autoimmune disease, our re-
sults are consistent with reported clinical studies in susceptible individ-
uals, e.g., infantswith hepatitis and cholestasis [56], and anautoimmune
adult with chronic hepatitis suffering from diarrhea with mucus, and
abdominal pain [57].
In conclusion, AIH induced by ConA could be could be sensitized by a
genetic backgroundwith iPLA2β deﬁciency, which leads to an induction
of duodenal apoptosis, villous atrophy, bowel inﬂammation and goblet
hyperplasia. Bile acid proﬁling revealed a defect in hepatic bile acid syn-
thesis which was regulated by intestinal FXR/FGF15 axis. The observed
increase of peripheral bile acids in our study could be used as a diagnos-
tic marker for intestinal damage during sensitized AIH. Our data are
consistent with clinical studies linking AIH to IBD [3], and it may be
worthwhile to investigate whether these patients would have a defect
in Pla2G6 gene as previously found in patients with neuroregenerative
dystrophy [58]. Our study emphasizes that the liver-to-gut axis injury
does exist during AIH in susceptible hosts.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2015.04.025.
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